In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Chugai Pharmaceutical Co. shares tumbled the most since 1977 after late-stage trial data on an obesity drug it licensed to ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...

(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...

Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again. Eli Lilly’s weight ...